Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,512Revenue $M118Net Margin (%)-140.7Altman Z-Score-1.5
Enterprise Value $M1,578EPS $-0.9Operating Margin %-136.2Piotroski F-Score5
P/E(ttm)--Beneish M-Score-2.5Pre-tax Margin (%)-140.1Higher ROA y-yY
Price/Book40.210-y EBITDA Growth Rate %--Quick Ratio4.0Cash flow > EarningsY
Price/Sales12.85-y EBITDA Growth Rate %--Current Ratio4.0Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-33.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-176.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M189ROIC % (ttm)-152.9Gross Margin Increase y-yY

Gurus Latest Trades with ARIA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARIAMichael Price 2015-03-31 Buy 0.6%$6.1 - $8.97
($7.39)
$ 8.029%New holding550,000
ARIAJoel Greenblatt 2015-03-31 Buy $6.1 - $8.97
($7.39)
$ 8.029%New holding16,344
ARIAGeorge Soros 2014-12-31 Sold Out -0.01%$5.02 - $7.46
($6.28)
$ 8.0228%Sold Out0
ARIAGeorge Soros 2014-09-30 Reduce-0.04%$5.01 - $6.5
($5.84)
$ 8.0237%Reduce 85.00%150,000
ARIAGeorge Soros 2014-06-30 Add0.02%$6.3 - $8.52
($6.89)
$ 8.0216%Add 100.00%1,000,000
ARIAGeorge Soros 2014-03-31 Reduce-0.08%$6.46 - $8.99
($7.75)
$ 8.023%Reduce 74.36%500,000
ARIAGeorge Soros 2013-12-31 Buy 0.11%$2.2 - $18.8
($5.16)
$ 8.0255%New holding1,950,000
ARIAGeorge Soros 2012-06-30 Sold Out -0.15%$14.6 - $17.82
($16.35)
$ 8.02-51%Sold Out0
ARIAGeorge Soros 2012-03-31 Buy 0.15%$12.73 - $16.32
($13.74)
$ 8.02-42%New holding635,000
ARIAGeorge Soros 2011-12-31 Sold Out -0.07%$8.03 - $12.5
($10.96)
$ 8.02-27%Sold Out0
ARIAGeorge Soros 2011-09-30 Buy 0.07%$7.63 - $13.34
($10.54)
$ 8.02-24%New holding496,847
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARIA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARIA: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CLACKSON TIMOTHY PPresident, R&D, CSO 2015-07-16Sell7,000$8.54-6.32view
Duvall Martin JEVP, CCO 2015-07-16Sell1,400$8.54-6.32view
FITZGERALD EDWARD MExecutive VP, CFO 2015-07-16Sell7,000$8.54-6.32view
Bollag Daniel MSr. VP, Reg. Affairs & Quality 2015-07-16Sell4,000$8.54-6.32view
Cantor Maria ESVP, Corporate Affairs 2015-07-16Sell4,000$8.54-6.32view
BERSTEIN DAVID LSVP, Chief IP Counsel 2015-07-16Sell4,000$8.54-6.32view
Haluska FrankSVP, Clinical R&D, CMO 2015-07-16Sell4,400$8.54-6.32view
FITZGERALD EDWARD MExecutive VP, CFO 2015-05-01Sell60,000$8.8-9.09view
CLACKSON TIMOTHY PPresident, R&D, CSO 2015-04-23Sell123,766$9.5-15.79view
BERSTEIN DAVID LSVP, Chief IP Counsel 2015-03-23Sell4,375$8.72-8.26view

Quarterly/Annual Reports about ARIA:

News about ARIA:

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
comment on ARIA Mar 15 2013 
comment on ARIA Mar 15 2013 
comment on ARIA May 16 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 

More From Other Websites
Celgene Corp. Earnings Analysis: By the Numbers Jul 30 2015
Who Really Won in the PDL and Ariad Royalty Deal? Jul 29 2015
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Jul 29 2015
ARIAD to Receive up to $200 Million Through Iclusig Non-Dilutive Synthetic-Royalty Financing with... Jul 29 2015
PDL BioPharma Completes Royalty Transaction with ARIAD Pharmaceuticals Jul 29 2015
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events Jul 27 2015
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 24 2015
ARIAD to Webcast Conference Call on Second Quarter 2015 Financial Results Jul 22 2015
ARIAD to Webcast Conference Call on Second Quarter 2015 Financial Results Jul 22 2015
The Good, The Bad, And The Ugly: A Journey Into Jonathan Soros’ Top Small-Cap Picks Jun 17 2015
ARIAD (ARIA) Presents Favorable Long-Term Data on Iclusig - Analyst Blog Jun 15 2015
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial Jun 12 2015
ARIAD and Paladin Announce Commercial Distribution Agreement for Iclusig (Ponatinib) in Canada Jun 10 2015
ARIAD to Present at the Goldman Sachs Annual Global Healthcare Conference Jun 08 2015
ARIAD to Present at the Goldman Sachs Annual Global Healthcare Conference Jun 08 2015
ARIAD Presents Updated Clinical Data on brigatinib in Patients with ALK+ Non-Small Cell Lung Cancer... Jun 01 2015
ARIAD Announces Long-Term Safety and Efficacy Data Of Ponatinib in Chronic-Phase Chronic Myeloid... May 31 2015
Is Ariad Pharmaceuticals a Buyout Candidate? May 29 2015
ARIAD Announces Data Presentations at the European Hematology Association (EHA) Congress May 22 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK